Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations

NCT04409145 is registered in ClinicalTrials.gov with Venthera, Inc., a BridgeBio company as lead sponsor.

NCT NCT04409145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04409145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations
Lead sponsor
Venthera, Inc., a BridgeBio company
Phase
Phase 1/2
Overall status
Terminated
Start date
October 1, 2020
Completion date
April 13, 2022
Enrollment
15 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

lymphatic malformation, venolymphatic malformation, venous malformation